Geode Capital Management LLC Buys 32,016 Shares of Agenus Inc. (NASDAQ:AGEN)

Geode Capital Management LLC boosted its stake in shares of Agenus Inc. (NASDAQ:AGEN) by 7.1% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 483,059 shares of the biotechnology company’s stock after acquiring an additional 32,016 shares during the period. Geode Capital Management LLC’s holdings in Agenus were worth $2,648,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Point72 DIFC Ltd acquired a new stake in shares of Agenus during the 2nd quarter worth $51,000. EP Wealth Advisors LLC bought a new stake in Agenus during the third quarter worth about $55,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Agenus during the second quarter worth about $106,000. HighTower Advisors LLC increased its holdings in Agenus by 46.1% in the 3rd quarter. HighTower Advisors LLC now owns 23,851 shares of the biotechnology company’s stock valued at $122,000 after buying an additional 7,530 shares during the period. Finally, Exchange Traded Concepts LLC raised its position in shares of Agenus by 52.0% in the 3rd quarter. Exchange Traded Concepts LLC now owns 27,543 shares of the biotechnology company’s stock valued at $151,000 after buying an additional 9,422 shares in the last quarter. 61.46% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “neutral” rating on shares of Agenus in a research report on Thursday, December 5th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat, Agenus has an average rating of “Hold” and a consensus target price of $10.00.

Agenus Trading Up 7.3 %

AGEN stock opened at $3.55 on Wednesday. The stock has a market capitalization of $83.28 million, a P/E ratio of -0.32 and a beta of 1.27. The firm has a 50-day moving average price of $3.25 and a 200-day moving average price of $5.87. Agenus Inc. has a 12 month low of $2.50 and a 12 month high of $19.69.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.